chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Headache; Soreness at injection site; Child received Moderna Booster dose (0.25 ml); First COVID-19 dose was from Pfizer & Moderna's COVID-19 booster dose (0.25 ml) in error for her second dose instead of Pfizer's COVID-19 dose for children; This spontaneous case was reported by a pharmacist and describes the occurrence of HEADACHE (Headache), VACCINATION SITE PAIN (Soreness at injection site), PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Child received Moderna Booster dose (0.25 ml)) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First COVID-19 dose was from Pfizer & Moderna's COVID-19 booster dose (0.25 ml) in error for her second dose instead of Pfizer's COVID-19 dose for children) in a 7-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: PFIZER BIONTECH COVID-19 VACCINE (Pfyzer vaccine as a first dose) in November 2021. Past adverse reactions to the above products included No adverse drug reaction with PFIZER BIONTECH COVID-19 VACCINE.    On 31-Dec-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 31-Dec-2021, the patient experienced HEADACHE (Headache), VACCINATION SITE PAIN (Soreness at injection site), PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Child received Moderna Booster dose (0.25 ml)) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First COVID-19 dose was from Pfizer & Moderna's COVID-19 booster dose (0.25 ml) in error for her second dose instead of Pfizer's COVID-19 dose for children). The patient was treated with IBUPROFEN for No adverse event, at an unspecified dose and frequency. On 31-Dec-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Child received Moderna Booster dose (0.25 ml)) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First COVID-19 dose was from Pfizer & Moderna's COVID-19 booster dose (0.25 ml) in error for her second dose instead of Pfizer's COVID-19 dose for children) had resolved. At the time of the report, HEADACHE (Headache) and VACCINATION SITE PAIN (Soreness at injection site) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 02-Jan-2022: Follow up received and it contains information about patient demographics and vaccination information and treatment information and new events were added.
Very runny nose, like 5-6 tissues per hour, cough, fussiness, 2-3 day's later fever ranging from 100.1-102.4. Loss of appetite for solid foods.
9:45- 30 min p 12 c/o nausea and vomiting, feeling fuzzy and clammy to touch. Lying left side B/P 108/62 P 70 T 98.6. Client had not eaten since AM. Given juice.
Patient is 17 years old and received Moderna, which is recommended for 18+. I contacted our state immunization branch and informed them of the incident. They states that according to CDC guidelines that patient is still eligible to receive the 2nd dose. Mother contacted by employee on 03/18/2021 informing her that vaccine was given but she should have been 18. I contacted parent on 3/22/2021 to inform her that patient is eligible to receive 2nd dose. Mother voiced understanding.
3:40 PM Telephone call from father - said his son just returned home and his ears are turning red and he is having trouble breathing. I immed put RN on phone. RN spoke with parent, instructed to go to ER. Immediately to closest ER. Father gave Benadryl.
12Feb92 pt recvd Engerix B for hepatitis prevention. 1 & 1/2 hrs later devel elevated blood pressure, tremors & dizziness. Taken to ER and recvd Procardia while in route.
Patient experienced localized allergic reaction. Around the shot was red. He said he experienced dizziness for 6 hrs of shot. We sent him to Drs. office.
At 3:30 pm I started to get a headache so I laid down to rest and often a couple of minutes after I started to feel muscle pain and fever I tried to make it threw the day with medication but by the next morning the fever and muscle pain was gone but i still had a headache I took 2 ibuprofen 200mg and after that I felt much better and have had any issues ever since.
Within 1 hour had a severe headache; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Within 1 hour had a severe headache) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEADACHE (Within 1 hour had a severe headache). At the time of the report, HEADACHE (Within 1 hour had a severe headache) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The concomitant medications were not reported.  The treatment information was not provided.
size of the palm of your hand; hot to touch; itching at injection site; left arm swelling at vaccination site; redness at injection site; This spontaneous case was reported by a consumer and describes the occurrence of ADVERSE EVENT (size of the palm of your hand), VACCINATION SITE WARMTH (hot to touch), VACCINATION SITE PRURITUS (itching at injection site), VACCINATION SITE SWELLING (left arm swelling at vaccination site) and VACCINATION SITE ERYTHEMA (redness at injection site) in a 97-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Asymptomatic COVID-19 in 2021. Concurrent medical conditions included Sulfonamide allergy. Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID), PARACETAMOL (TYLENOL), GABAPENTIN and OXYCODONE HYDROCHLORIDE, PARACETAMOL (PERCOCET [OXYCODONE HYDROCHLORIDE;PARACETAMOL]) for an unknown indication.    On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Mar-2021, the patient experienced ADVERSE EVENT (size of the palm of your hand), VACCINATION SITE WARMTH (hot to touch), VACCINATION SITE PRURITUS (itching at injection site), VACCINATION SITE SWELLING (left arm swelling at vaccination site) and VACCINATION SITE ERYTHEMA (redness at injection site). At the time of the report, ADVERSE EVENT (size of the palm of your hand), VACCINATION SITE WARMTH (hot to touch), VACCINATION SITE PRURITUS (itching at injection site), VACCINATION SITE SWELLING (left arm swelling at vaccination site) and VACCINATION SITE ERYTHEMA (redness at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications included blood pressure medication and antibiotic.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 22-Jun-2021: information regarding second dose updated NNI FOR DOSE ONE
Left axilla swelling and lymph nodes; Left upper arm swelling (injected arm). Left arm noticeably larger than right arm; Left axilla swelling; Difficult raising injected left arm; This is a spontaneous report received from a non-contactable reporter (other healthcare professional). The reporter is the patient.  A 28-year-old female patient (not pregnant) received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), administered in left arm, administration date 30Nov2021 (Batch/Lot number: FF8841) at the age of 28 years as dose 2, single for COVID-19 immunisation. The patient's relevant medical history was not reported. Concomitant medications included: PRENATAL, NORETHINDRONE and IBUPROFEN. Vaccination history included: BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, DOSE 1, SINGLE, Lot Number: FF8841, Route of administration: Unspecified, Anatomical site: left arm), administration date: 09Nov2021, when the patient was 28 years old, for COVID-19 immunisation. The following information was reported: PERIPHERAL SWELLING (non-serious), SWELLING (non-serious), LYMPHADENOPATHY (non-serious), MOBILITY DECREASED (non-serious) all with onset 30 Nov2021, outcome "not recovered" and all described as "Left upper arm swelling (injected arm). Left arm noticeably larger than right arm"; "Left axilla swelling and lymph nodes"; "Difficult raising injected left arm". Therapeutic measures were not taken as a result of peripheral swelling, swelling, lymphadenopathy and joint range of mobility decreased.  Additional Information: The patient had no known allergies. It was unknown whether the patient received any other vaccines within four weeks prior to COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  No follow-up attempts are possible. No further information is expected.
difficulty breathing; shortness of breath; can't hold breath for longer than 6 seconds; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (difficulty breathing), DYSPNOEA (shortness of breath) and DYSPNOEA (can't hold breath for longer than 6 seconds) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DYSPNOEA (difficulty breathing), DYSPNOEA (shortness of breath) and DYSPNOEA (can't hold breath for longer than 6 seconds). At the time of the report, DYSPNOEA (difficulty breathing), DYSPNOEA (shortness of breath) and DYSPNOEA (can't hold breath for longer than 6 seconds) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication were reported.  No treatment information was reported.   Reporter did not allow further contact
Breakthrough case admission after 3 vaccines Pfizer 4/21/21 lot# Ew0171;  Pfizer 5/12/21 lot# Ew0177;  Pfizer 12/27/21 lot# 330258D
Chills, fever, red shoulder. Evaluated 11/11/12 in urgent care: no fever but BP uncharacteristically low SBP 80.
at first it was just nausea. On April 16 around 1 pm i started throwing up and didnt stop for 5 days. I had the chills and body aches. My head did not hurt though, but my stomach felt like it was on fire and about to burst. I started getting sick. I went to the ER to hopefully get some fluids and something for the nausea and stomach pain. They gave me 2 bags of fluid and anti nausea meds. This helped till i got home. And then i started throwing up again non stop till Tuesday April 18. My husband took me to ER to admit me again.
This spontaneous report as received from a physician refers to a female patient of unknown age with no pertinent medical history and no drug reactions/allergies. No other co-suspects were reported. There were no concomitant medications. On 11-MAR-2013 the patient was vaccinated with VARIVAX (merck) (lot# and route unknown). On 11-MAR-2013, the patient experienced redness at the injection site. No lab and no treatments given for the event. The patient had sought medical attention via her mother called the office. The outcome was reported as recovered on an unknown date. Action taken was not provided. The reporter did not provide assessment of the relationship of the adverse event to the suspect therapy. Additional information is not expected.
psoriasis on back of scalp has cleared up / Unexpected benefit; Fever following second dose of Shingrix; Rapid heartbeat following second dose of Shingrix; This case was reported by a consumer via and described the occurrence of fever in a 64-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included psoriasis. Concomitant products included Herpes zoster (Shingrix).   In December 2020, the patient received the 2nd dose of Shingrix (intramuscular). In December 2020, less than a week after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced fever, heartbeats increased and unexpected therapeutic effect. In December 2020, the outcome of the fever and heartbeats increased were recovered/resolved. On an unknown date, the outcome of the unexpected therapeutic effect was unknown.   It was unknown if the reporter considered the fever and heartbeats increased to be related to Shingrix. The reporter considered the unexpected therapeutic effect to be related to Shingrix.  Additional details were provided as follows:  The patient reported for himself. Both doses were administered intramuscularly in left arm.  Lot numbers and dose volumes were not known. First dose of Shingrix was administered just over two months ago, and the second dose of Shingrix was administered one week ago before the date of reporting. The patient got both doses of the Shingrix vaccine and everything was fine but he was wondering if Shingrix could boost the immune system because he had noticed that his scalp psoriasis had cleared up.  The psoriasis on back of scalp that occurred before receiving either dose of Shingrix had disappeared two days later after 2nd dose of Shingrix (unexpected benefit).  The patient had one day of fever and rapid heartbeat following second dose of Shingrix. The reporter provided limited information. The reporter consented to HCP follow-up but was unable to provide contact Information. Patient's e-mail address was collected for follow-up.
diagnosed with Covid; diagnosed with Covid; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 56-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 06Mar2021 at 13:00 as dose 1, single (Lot number: EP6955), in left arm, on 03Apr2021 at 13:00 as dose 2, single (Lot number: ER8729), in left arm and on 11Oct2021 at 13:00 as dose 3 (booster), single (Lot number: 30145BA) at the age of 55 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "genetic hypertrophic cardiomyopathy" (unspecified if ongoing), notes: (take Verapamil for it); "dry eye (Restasis)" (unspecified if ongoing), notes: dry eye (Restasis); "hysterectomy" (unspecified if ongoing), notes: total hysterectomy at age 45 due to fibroids on HRT (Vivelle) for early menopause; "menopause" (unspecified if ongoing), notes: total hysterectomy at age 45 due to fibroids on HRT (Vivelle) for early menopause. Concomitant medication(s) included: VERAPAMIL; VIVELLE [ESTRADIOL]; RESTASIS; FISH OIL Multi-vitamin, turmeric. The following information was reported: PYREXIA (non-serious) with onset 01Apr2022, outcome "recovered" (Apr2022), described as "having a fever"; COUGH (non-serious) with onset Apr2022, outcome "recovered" (15Apr2022), described as "Bad cough"; COVID-19 (medically significant) with onset Apr2022, outcome "recovered" (Apr2022), VACCINATION FAILURE (medically significant), outcome "unknown" and all described as "diagnosed with Covid". The events "diagnosed with covid" and "having a fever" required emergency room visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Apr2022) Positive; (Apr2022) Negative, notes: a week later. Therapeutic measures were taken as a result of vaccination failure, covid-19, pyrexia. Therapeutic measures were not taken as a result of cough included Paxlovid.
(1) Extensive rash of erythema toxicum about 6 hours after injection. (2) Possibly exacerbated Jaundice due to breast feeding  5/2/08 Reviewed PCP medical records 4/11-4/18/2008.   Records reveal patient experienced decreased activity x 1 day.  5/2/08 Reviewed hospital medical records of 4/12-4/13/2008. FINAL DX: Hyperbilirubinemia & rash on abdomen/groin. Records reveal patient experienced decreased activity x 1 day.  Icteric sclera, rash & jaundice to lower chest.  Tx w/antibiotic ointment; no phototherapy done.  Seen by pediatric hospitalist who felt rash likely erythema toxicum & elevated bilirubin likely physiologic.  D/C to home to f/u w/PCP.
This spontaneous report as received from a pharmacist refers to a 65 year old female patient with no medical history and drug reaction/allergy. On 04-APR-2014 the patient was vaccinated with a dose of ZOSTAVAX, 0.65 ml, subcutaneous. Concomitant vaccine included BOOSTRIX. On 04-APR-2014 the patient experienced red lump at injection site where ZOSTAVAX was given. On 07-APR-2014, the patient developed nerve pain and blister at injection site. The patient contacted pharmacist and put ice and heat on blister. There was no laboratory test performed. The outcome of the events were reported as not recovered/not resolved. Additional information has been requested.
Dose administered to 26 patients from 5 vials stored in the fridge for more than 30 days; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered to 26 patients from 5 vials stored in the fridge for more than 30 days) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033H21A) for COVID-19 vaccination.     Concurrent medical conditions included HIV disease. Concomitant products included BICTEGRAVIR SODIUM, EMTRICITABINE, TENOFOVIR ALAFENAMIDE FUMARATE (BIKTARVY) for an unknown indication.    On 31-Jan-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Jan-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered to 26 patients from 5 vials stored in the fridge for more than 30 days). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered to 26 patients from 5 vials stored in the fridge for more than 30 days) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Reporter stated that Dose administered to 26 patients from 5 vials stored in the fridge for more than 30 days. on 28-Dec-2021 vials was initially stored in refrigerator. vials did not undergo any temperature excursions. Caller did not know if any of the patients experienced any  symptoms after vaccination.  Reporter stated that All the patients had a clinical history of HIV, and all of them were under treatment for this illness.  Reporter stated did not know if any treatment was given to any of the patients, as she did not know if any of them experienced any symptoms after vaccination.  Patient had no known allergy.
5 day onset progressive half dollar size, raised, red, painful lump to right thigh. Patient had varicella om right thigh. Mom gave ibuprofen for pain in right thigh.  Mom scheduled follow up with provider on 09/26/2022.
Erythema extending from the shoulder to 1" above the elbow on the exterior surface of the (R) upper arm. Started and noticed by the mother on the next day 9/27/08 in the morning. Progressively worsened with intense itching at the site. Mild induration also seen. 5-6 linear scabbed abrasions (3-4 mm ) in the same area. Sx gradually decreased over 9/28/08 and 9/29/08.
Almost 2 months post vax, this pt presented at the physician's office for frequent cough. Labs were conducted. He presented at the office the next day and was sent to the hospital the following day and admitted due to worsening of cough. Pertussis was confirmed.   60 day follow-up received 11/14/00 provided no additional data.
Abnormal headaches occurred in Jan 2021, headaches would worsen at night time and cause sharp pains behind my head. Persisted for more than 1 month and requested health care provider advice, which i was then scheduled an in-person visit. Nurse recommended daily health exercises and wind down time before bed. Also recommended consistent sleep schedules to reduce symptoms. I attempted to adopt some recommendations for a few weeks and noticed slight improvements in my headaches and nightly sharp pains, after about a couple months the symptoms disappeared.
Allergic Reaction; This spontaneous case was reported by a patient and describes the occurrence of ALLERGY TO VACCINE (Allergic Reaction) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ALLERGY TO VACCINE (Allergic Reaction). At the time of the report, ALLERGY TO VACCINE (Allergic Reaction) outcome was unknown.            Concomitant product use was not provided by the reporter. Treatment information was not provided.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 31-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: ALLEGRA 24 HOUR taken for hypersensitivity. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID-19 treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Rebound symptoms several days after completing course of PAXLOVID.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
It flared up my left hip joint the evening I got it. It still flares up on a daily basis. It had gotten a little better but following the second dose it reignited. I don't know if getting the shingrix vaccine is the reason it still flares. I got the shingrix vaccine in 11/2020. Right hip and right shoulder joint flare. In April, I got a trigger thumb and that joint was painful for a couple months. It's been unusual joint pain for me. I did have a fall on 9/2020, but that was getting better. It had eased A LOT. Once I got the vaccine, everything got bad again. My position does not matter, regardless if I am sitting, standing, walking, it hurts.
Fever up to 102.3, severe headache, body aches, chills, and nausea for 2 days.